Cargando…

Peripheral blood cellular dynamics of rheumatoid arthritis treatment informs about efficacy of response to disease modifying drugs

Rheumatoid arthritis (RA) is an autoimmune disease characterized by systemic inflammation and is mediated by multiple immune cell types. In this work, we aimed to determine the relevance of changes in cell proportions in peripheral blood mononuclear cells (PBMCs) during the development of disease an...

Descripción completa

Detalles Bibliográficos
Autores principales: Hedman, Åsa K., Winter, Eitan, Yoosuf, Niyaz, Benita, Yair, Berg, Louise, Brynedal, Boel, Folkersen, Lasse, Klareskog, Lars, Maciejewski, Mateusz, Sirota-Madi, Alexandra, Spector, Yael, Ziemek, Daniel, Padyukov, Leonid, Shen-Orr, Shai S., Jelinsky, Scott A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10284888/
https://www.ncbi.nlm.nih.gov/pubmed/37344505
http://dx.doi.org/10.1038/s41598-023-36999-0
_version_ 1785061491196559360
author Hedman, Åsa K.
Winter, Eitan
Yoosuf, Niyaz
Benita, Yair
Berg, Louise
Brynedal, Boel
Folkersen, Lasse
Klareskog, Lars
Maciejewski, Mateusz
Sirota-Madi, Alexandra
Spector, Yael
Ziemek, Daniel
Padyukov, Leonid
Shen-Orr, Shai S.
Jelinsky, Scott A.
author_facet Hedman, Åsa K.
Winter, Eitan
Yoosuf, Niyaz
Benita, Yair
Berg, Louise
Brynedal, Boel
Folkersen, Lasse
Klareskog, Lars
Maciejewski, Mateusz
Sirota-Madi, Alexandra
Spector, Yael
Ziemek, Daniel
Padyukov, Leonid
Shen-Orr, Shai S.
Jelinsky, Scott A.
author_sort Hedman, Åsa K.
collection PubMed
description Rheumatoid arthritis (RA) is an autoimmune disease characterized by systemic inflammation and is mediated by multiple immune cell types. In this work, we aimed to determine the relevance of changes in cell proportions in peripheral blood mononuclear cells (PBMCs) during the development of disease and following treatment. Samples from healthy blood donors, newly diagnosed RA patients, and established RA patients that had an inadequate response to MTX and were about to start tumor necrosis factor inhibitors (TNFi) treatment were collected before and after 3 months of treatment. We used in parallel a computational deconvolution approach based on RNA expression and flow cytometry to determine the relative cell-type frequencies. Cell-type frequencies from deconvolution of gene expression indicate that monocytes (both classical and non-classical) and CD4(+) cells (T(h)1 and T(h)2) were increased in RA patients compared to controls, while NK cells and B cells (naïve and mature) were significantly decreased in RA patients. Treatment with MTX caused a decrease in B cells (memory and plasma cell), and a decrease in CD4 T(h) cells (T(h)1 and T(h)17), while treatment with TNFi resulted in a significant increase in the population of B cells. Characterization of the RNA expression patterns found that most of the differentially expressed genes in RA subjects after treatment can be explained by changes in cell frequencies (98% and 74% respectively for MTX and TNFi).
format Online
Article
Text
id pubmed-10284888
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-102848882023-06-23 Peripheral blood cellular dynamics of rheumatoid arthritis treatment informs about efficacy of response to disease modifying drugs Hedman, Åsa K. Winter, Eitan Yoosuf, Niyaz Benita, Yair Berg, Louise Brynedal, Boel Folkersen, Lasse Klareskog, Lars Maciejewski, Mateusz Sirota-Madi, Alexandra Spector, Yael Ziemek, Daniel Padyukov, Leonid Shen-Orr, Shai S. Jelinsky, Scott A. Sci Rep Article Rheumatoid arthritis (RA) is an autoimmune disease characterized by systemic inflammation and is mediated by multiple immune cell types. In this work, we aimed to determine the relevance of changes in cell proportions in peripheral blood mononuclear cells (PBMCs) during the development of disease and following treatment. Samples from healthy blood donors, newly diagnosed RA patients, and established RA patients that had an inadequate response to MTX and were about to start tumor necrosis factor inhibitors (TNFi) treatment were collected before and after 3 months of treatment. We used in parallel a computational deconvolution approach based on RNA expression and flow cytometry to determine the relative cell-type frequencies. Cell-type frequencies from deconvolution of gene expression indicate that monocytes (both classical and non-classical) and CD4(+) cells (T(h)1 and T(h)2) were increased in RA patients compared to controls, while NK cells and B cells (naïve and mature) were significantly decreased in RA patients. Treatment with MTX caused a decrease in B cells (memory and plasma cell), and a decrease in CD4 T(h) cells (T(h)1 and T(h)17), while treatment with TNFi resulted in a significant increase in the population of B cells. Characterization of the RNA expression patterns found that most of the differentially expressed genes in RA subjects after treatment can be explained by changes in cell frequencies (98% and 74% respectively for MTX and TNFi). Nature Publishing Group UK 2023-06-21 /pmc/articles/PMC10284888/ /pubmed/37344505 http://dx.doi.org/10.1038/s41598-023-36999-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Hedman, Åsa K.
Winter, Eitan
Yoosuf, Niyaz
Benita, Yair
Berg, Louise
Brynedal, Boel
Folkersen, Lasse
Klareskog, Lars
Maciejewski, Mateusz
Sirota-Madi, Alexandra
Spector, Yael
Ziemek, Daniel
Padyukov, Leonid
Shen-Orr, Shai S.
Jelinsky, Scott A.
Peripheral blood cellular dynamics of rheumatoid arthritis treatment informs about efficacy of response to disease modifying drugs
title Peripheral blood cellular dynamics of rheumatoid arthritis treatment informs about efficacy of response to disease modifying drugs
title_full Peripheral blood cellular dynamics of rheumatoid arthritis treatment informs about efficacy of response to disease modifying drugs
title_fullStr Peripheral blood cellular dynamics of rheumatoid arthritis treatment informs about efficacy of response to disease modifying drugs
title_full_unstemmed Peripheral blood cellular dynamics of rheumatoid arthritis treatment informs about efficacy of response to disease modifying drugs
title_short Peripheral blood cellular dynamics of rheumatoid arthritis treatment informs about efficacy of response to disease modifying drugs
title_sort peripheral blood cellular dynamics of rheumatoid arthritis treatment informs about efficacy of response to disease modifying drugs
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10284888/
https://www.ncbi.nlm.nih.gov/pubmed/37344505
http://dx.doi.org/10.1038/s41598-023-36999-0
work_keys_str_mv AT hedmanasak peripheralbloodcellulardynamicsofrheumatoidarthritistreatmentinformsaboutefficacyofresponsetodiseasemodifyingdrugs
AT wintereitan peripheralbloodcellulardynamicsofrheumatoidarthritistreatmentinformsaboutefficacyofresponsetodiseasemodifyingdrugs
AT yoosufniyaz peripheralbloodcellulardynamicsofrheumatoidarthritistreatmentinformsaboutefficacyofresponsetodiseasemodifyingdrugs
AT benitayair peripheralbloodcellulardynamicsofrheumatoidarthritistreatmentinformsaboutefficacyofresponsetodiseasemodifyingdrugs
AT berglouise peripheralbloodcellulardynamicsofrheumatoidarthritistreatmentinformsaboutefficacyofresponsetodiseasemodifyingdrugs
AT brynedalboel peripheralbloodcellulardynamicsofrheumatoidarthritistreatmentinformsaboutefficacyofresponsetodiseasemodifyingdrugs
AT folkersenlasse peripheralbloodcellulardynamicsofrheumatoidarthritistreatmentinformsaboutefficacyofresponsetodiseasemodifyingdrugs
AT klareskoglars peripheralbloodcellulardynamicsofrheumatoidarthritistreatmentinformsaboutefficacyofresponsetodiseasemodifyingdrugs
AT maciejewskimateusz peripheralbloodcellulardynamicsofrheumatoidarthritistreatmentinformsaboutefficacyofresponsetodiseasemodifyingdrugs
AT sirotamadialexandra peripheralbloodcellulardynamicsofrheumatoidarthritistreatmentinformsaboutefficacyofresponsetodiseasemodifyingdrugs
AT spectoryael peripheralbloodcellulardynamicsofrheumatoidarthritistreatmentinformsaboutefficacyofresponsetodiseasemodifyingdrugs
AT ziemekdaniel peripheralbloodcellulardynamicsofrheumatoidarthritistreatmentinformsaboutefficacyofresponsetodiseasemodifyingdrugs
AT padyukovleonid peripheralbloodcellulardynamicsofrheumatoidarthritistreatmentinformsaboutefficacyofresponsetodiseasemodifyingdrugs
AT shenorrshais peripheralbloodcellulardynamicsofrheumatoidarthritistreatmentinformsaboutefficacyofresponsetodiseasemodifyingdrugs
AT jelinskyscotta peripheralbloodcellulardynamicsofrheumatoidarthritistreatmentinformsaboutefficacyofresponsetodiseasemodifyingdrugs